Conflicts, Immunity, and a Call for Enlightenment in Biomedical Innovation
A troubling underbelly of U.S. biomedical innovation—conflicts of interest at the FDA and NIH that stifle pioneers like themselves, risking America’s global edge to China’s unchecked rise. Their immune system focus, spotlighting NK cells as a "missing link," drives both their BioShield project and practical health advice, challenging the pharma complex’s narrow lens. With $3 billion personally invested and a platform in the LA Times, they stand at a crossroads: a potential "period of enlightenment" under reformist leadership could validate their decades-long fight, amplifying T-cell solutions and reasserting U.S. leadership. Absent such change, their warnings of corruption and decline may prove prophetic, with BioShield remaining a sidelined testament to what could have been.
